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Abstract
In order to improve medication safety, more epidemiological data on the prevalence and
clinical relevance of drug interactions are required. We developed an interface for mass
analysis using the Clinical Decision Support Software (CDSS) MediQ and a multidimensional
classification (Zurich Interaction System (ZHIAS)) incorporating the Operational Classification
of Drug Interactions (ORCA). These were applied to 359,207 cross-sectional prescriptions from
84,607 psychiatric inpatients collected through the international AMSP program. MediQ
issued 2,308 "high" and 71,112 "average" danger interaction alerts. Among these, after ORCA
reclassification, there were 151 contraindicated and 4,099 provisionally contraindicated
prescriptions. The ZHIAS provided further detailed categorical information on recommended
management and specific increased risks (QTc prolongation being the most frequent one)
associated with interactions. We developed a highly efficient solution for the identification and
classification of drug interactions in large prescription data sets; this solution may help to
reduce the frequency of overalerting and improve acceptance of the efficacy of CDSS in
reducing the occurrence of potentially harmful drug interactions.
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ABSTRACT 
 
In order to improve medication safety more epidemiological data on the prevalence and 
clinical relevance of drug interactions is required. We developed an interface for mass 
analysis with the Clinical Decision Support Software (CDSS) MediQ and a 
multidimensional classification (ZHIAS) incorporating the Operational Classification of 
Drug Interactions (ORCA). These were applied to 359,207 cross-sectional prescriptions 
from 84,607 psychiatric inpatients collected through the international AMSP program. 
MediQ issued 2,308 “high” and 71,112 “average” danger interaction alerts. Among those 
there remained 151 contraindicated and 4,099 provisionally contraindicated prescriptions 
after ORCA reclassification. ZHIAS provided further detailed categorical information on 
recommended management and specific increased risks associated with interactions, 
where QTc prolongation was the single most frequent. We developed a highly efficient 
solution for the identification and classification of drug interactions in large prescription 
datasets that may support the reduction of over-alerting and improve acceptance and 
efficacy of CDSS to reduce critical drug interactions. 
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INTRODUCTION 
 
Drug interactions causing adverse drug events (ADE) and increased costs represent important 
challenges for pharmacotherapy (1-3). Only a small fraction of (potential) drug interactions lead 
to ADE, and only a part of all ADE are related to interactions (4). However, ADE resulting from 
interactions are of particular importance from a preventive perspective because they are 
avoidable and therefore constitute suitable targets for preventive measures. Furthermore, ADE 
related to interactions may often remain unrecognized as such and their clinical relevance 
therefore be underestimated by prescribing physicians. Within that context psychiatric patients 
are of special interest for several reasons. The psychiatric population is growing older, which 
independently increases the susceptibility to ADE as well as the prevalence of non-psychiatric 
diseases and therefore polypharmacy (5, 6). Furthermore, many new psychopharmacologic drugs 
have been developed and are now increasingly used for previously undertreated psychiatric 
conditions. At the same time drugs acting on the central nervous system are among the leading 
ones to cause ADE (1, 7). These considerations suggest a substantial absolute number of ADE 
related to drug interactions in psychiatric populations. 
 
Clinical Decision Support Software (CDSS) can sensitively detect interacting drug combinations 
and has therefore been promoted as a powerful tool to improve medication safety (8, 9). 
However, some recent studies that looked at the use of CDSS and its effective impact on 
medication safety concluded that over-alerting and lack of practical management 
recommendations often cause physicians to disregard even severe alerts (10-13). One review 
found that between 49% and 96% of alerts are ignored or overridden (14). This phenomenon, 
sometimes referred to as “alert fatigue”, strongly limits the acceptance of CDSS and therefore its 
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efficacy to improve medication safety in real-life settings (15, 16). Furthermore, classification of 
drug interactions is a necessary but challenging task for all CDSS, and it remains largely 
unknown how different categories correlate with clinical relevance of alerts. Newer algorithms 
aim to address this issue (17), and one of the most widely recognized classifications is the 
Operational Classification of Drug Interactions (ORCA) (18). ORCA particularly focuses on 
clinical management and identification of interactions that require medical interventions or 
monitoring (19). 
 
Only few studies investigated medication safety and drug interactions in psychiatry while 
addressing the possible role of CDSS (7, 20). More epidemiological studies are warranted in 
order to quantify the prevalence and evaluate the clinical relevance of drug interactions in 
psychiatric patients. In order to achieve this task efficient solutions for the analysis of 
interactions in large population-based datasets are needed. The current study therefore had the 
following major objectives: First, development of a solution for mass analysis of prescription 
data with CDSS. Second, development of an extended interaction classification that focuses on 
clinical management decisions. Third, use of these newly developed methods in order to evaluate 
the frequency and clinical relevance of drug interactions in a psychiatric inpatient population. 
 
 
RESULTS 
The original AMSP raw dataset contained data of 88,029 patients with 334,056 prescriptions of 
commercial drug products. The only two exclusion criteria were either prescriptions of 
unidentifiable drug products, i.e. the active ingredient could not be ascertained, or a prescribed 
substance that was not comprised in the MediQ database. Accordingly we had to exclude 39 
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unidentifiable products and 353 ingredients that were not comprised in the MediQ database. 
However, those 392 products accounted only for 7,079 (2.1%) of all prescriptions, and almost all 
of these products were herbal or homeopathic multi-ingredient preparations or food supplements 
with little relevance for drug interactions (whereas e.g. St. John’s worth was included). 
Consequently only 3,422 (3.9%) patients with unidentifiable or not analyzable prescriptions had 
to be excluded. Splitting of prescriptions for multi-ingredient drug products led to the final 
dataset comprising 84,607 patients with 359,207 prescriptions for distinct active substances. 
Characteristics of the study population are presented in Table E1. Schizophrenia (34.3%) and 
mood (affective) disorders (30.5%) were the leading primary diagnoses. Source countries of the 
patients were Germany (74.8%), Switzerland (17.9%), Austria (6.4%), Belgium (0.6%) and 
Hungary (0.3%). The mean and median of concomitant prescriptions per patient was 3.9 and 3, 
respectively, and 5% of all patients had polypharmacy with at least 9 concomitantly prescribed 
drugs. Frequency of prescriptions by major drug categories and for the 25 most commonly used 
specific substances out of a total of 798 distinct substances are presented in Tables E2 and E3, 
respectively. Antipsychotics and antidepressants were the most frequently prescribed drug 
classes, olanzapine and mirtazapine being the leading substances, followed by cardiovascular 
agents and anxiolytics / sedatives. Lorazepam was the most frequently prescribed single drug. 
 
Automated mass analysis for interactions using MediQ resulted in 387,922 interaction alerts and 
comments that involved 488 different substances and affected 79% of the study population. 
However, 13.7% had a prescription for only one substance anyway, and therefore only 7.3% had 
polypharmacy but no interaction alerts. The mean number of MediQ alerts and comments per 
patient was 4.6, 12.0% of all patients had more than ten alerts and comments, and one patient 
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with 30 concomitant substances had 87 alerts and comments. Distribution of the number of alerts 
per patient is also shown in Figure E1. Distribution of MediQ grading of all alerts is shown in 
Figure 1. About one third of all alerts were in fact comments regarding the absence of a 
clinically relevant interaction (“no interaction”) or poorly documented possible interactions of 
questionable clinical relevance. High danger interactions accounted for only 0.6 % of all alerts, 
and average danger alerts for 18.3 %. 
 
With regard to drugs, 77.1% of the 146,840 prescriptions involved in average or high danger 
alerts were substances acting on the central nervous system, most frequently antipsychotics 
(40.3%), followed by antidepressants (15.4%) and anxiolytics, sedatives and hypnotics (9.9%). 
Cardiovascular agents (11.4%) were the most frequent non-centrally acting drugs involved in 
interaction alerts. Among the high danger alerts drugs acting on the central nervous system were 
involved in 75.0 % of alerts, and antipsychotics (36.5%) and antidepressants (33.6%) were most 
frequently represented. Cardiovascular agents were involved in 19.0% of all high danger alerts. 
Figure E2 provides an additional overview of the frequency of interactions between therapeutic 
drug categories. 
Table 1 lists the top 20 substances that were most frequently involved in high danger MediQ 
interaction alerts. Interestingly, only three drugs, namely clozapine, fluvoxamine and lithium, 
accounted for more than half of all high danger alerts. Table 2 describes the intrinsic risk 
associated with a given substance to cause a high danger interaction alert in our study population. 
Here, amiodarone, pimozide and fluvoxamine rank as the top three substances.  
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Looking at specific combinations, the most frequent drug combinations associated with high 
danger alerts are presented in Table 3. Of note, only 20 combinations were responsible for two 
thirds of all high danger alerts, and adverse central nervous system effects and QTc prolongation 
dominated the associated adverse effects. The most frequent drug combinations involved in 
average danger alerts were neuroleptics plus benzodiazepines, linked to an increased risk of 
sedation, and the top 20 specific combinations are also presented in Table E4. 
 
Finally, we reclassified all 201 individual MediQ high danger combinations and the 20 most 
frequent average danger combinations according to the extended ZHIAS classification. Results 
are shown in Figure 2 (ORCA classification only) and Table 4. Based on ORCA 39 (19%) of all 
interactions previously identified as high danger were classified as contraindicated, and another 
87 (43.3%) as provisionally contraindicated. Among the 20 most frequent moderate interactions, 
no combination was classified as contraindicated and only 4 (20%) as provisionally 
contraindicated. We also compared our assessments with the ORCA classes according to 
Hansten and Horn’s interaction compendium (21). Out of the 221 evaluated high and average 
danger combinations 138 were not found there, and for the remaining 83 our assessment deviated 
for 32 combinations: in 29 our classification was more stringent, whereas in 3 we had assigned a 
lower risk category. Table 4 shows the frequency of ZHIAS assessments calculated for the 
complete study population along with the detailed assignment to the extended categories. 
Clinical recommendations were provided for all evaluated interactions that fall into ORCA 
classes 1 to 3. Of note, even among the provisionally contraindicated prescriptions, we judged 
that one third was likely prescribed deliberately because the benefit usually outweighs the risk if 
it is appropriately monitored. Regarding possible adverse effects it is of interest that more than 
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half of all high danger interactions were associated with an increased risk of QTc prolongation. 
Almost one third of increased risks affected the central nervous system, serotonin toxicity being 
the most frequent. 
 
Finally, we also looked at trends over time regarding polypharmacy and prescriptions of MediQ 
high danger combinations. Whereas polypharmacy continuously increases, the proportion of 
patients with high danger interactions rather decreases (Figure 3). Further analyses explored the 
contribution of specific risks associated with interactions to all high danger alerts comparing the 
time from 1994 to 2000 vs. 2001 to 2008.  The proportion of risks for extrapyramidal symptoms 
changed from 8.0 to 2.7 % (p<0.001), for sedating effects from 10.9% to 4.9% (p<0.001), for 
seizures from 14.6% to 40.8 % (p<0.001), and for QTc prolongations it remained at around 62% 
(p=0.2). 
 
 
DISCUSSION 
 
To our best knowledge we present the first study that used a customized interface for mass 
analysis of drug interactions with CDSS in an epidemiological database. This innovative 
approach allowed us to identify and further evaluate potential drug interactions under natural 
conditions in a large psychiatric inpatient population with previously unachieved efficiency. At 
the same time we also provide a methodological solution for large-scale evaluation of CDSS 
using real-life prescription data, and we used a new interaction classification system in order to 
evaluate clinical relevance, management implications and associated ADE. 
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MediQ covered the active substances of 97.9% of all drug prescriptions in the studied 
population, and many combinations that are not even found in Hansten and Horn’s 
comprehensive collection, which is remarkable and likely reflects its comprehensive data 
collection particularly on central nervous system drugs in combination with the fact that our 
dataset was limited to psychiatric patients. Vice versa our dataset covered 8,840, i.e. 44% of 
about 20,000 combinations that are contained in the MediQ database. Consequently MediQ 
generated a very large number of alerts suggesting high sensitivity for that task. At the same 
time, an average number of 4.6 alerts and comments per patient with a maximum of 87 alerts in a 
single patient raises the question of unnecessary over-alerting. This can lead to non-
discriminative overriding even of severe alerts and therefore compromise the efficacy of CDSS 
to improve medication safety in clinical practice (15, 22). Although the display can be limited to 
high danger alerts, our and others’ results suggest that this is not a reliable measure to identify 
those interactions that require active management (18). The ORCA classification has been 
designed with that issue in mind, and we have now extended this classification and applied the 
resulting ZHIAS system to a real-life population. First, reclassification according to ORCA 
suggests that about 35% of distinct high danger MediQ alerts (cf. Figure 2), or 30% of those 
occurring in our population (cf. Table 4) only relate to a conditionally increased risk, and that 
combinations with an absolute contraindication are very rare. Second, extended evaluation 
according to ZHIAS provides categorical management recommendations and suggests that in 
many instances a combination may have been prescribed deliberately because the benefit likely 
outweighs possible risks of a theoretical interaction. In many cases appropriate monitoring or 
reduced doses may be efficacious measures to control a potential risk. The additional 
dichotomous information that ZHIAS provides regarding mechanisms and specific possible ADE 
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may then be of high practical value because it can be readily displayed in appropriately designed 
CDSS. For example, a warning about increased plasma levels can be provided by a specific icon 
and point towards a possible need for dose reduction; icons for specific ADE with an increased 
risk can stimulate the physician to monitor for according symptoms and signs, or help identifying 
an ADE as such if it has already occurred. Another important feature is that specific ADE shown 
by ZHIAS can directly point towards risk factors. Advanced CDSS could implement that 
information in patient-specific warning algorithms. If for example there were an increased risk of 
hyponatremia, the CDSS could automatically retrieve current plasma sodium values from the 
hospital’s electronic laboratory results system and automatically recognize hyponatremia as a 
possible ADE. 
Another intriguing implication of our study is the option to conduct retrospective analyses that 
can subsequently guide the development of preventive strategies. These can target those drug 
interactions that were identified to occur with a critical frequency and actually led to adverse 
drug effects in a given setting. Our results indicate that the creation of a locally customized “Top 
10 Interaction List” would likely cover a large part of all critical interactions. 
 
The time trends analyses of our study also revealed additional interesting and reassuring 
findings. Although we observed a clear trend of increasing polypharmacy, this was apparently 
not associated with an increasing risk of high danger interactions. Possible explanations would 
be more favorable overall safety profiles or specifically a lower potential for interactions of 
newer psychotherapeutics. Some trends like the lower risk of extrapyramidal symptoms may be 
readily explained by a decreasing use of older antipsychotics, but only further more detailed 
analyses will provide robust explanations. In that context, the role of regulatory agencies may 
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also be of interest. On the one hand, these may already have contributed to safer prescribing 
through their involvement in drug development and labeling; and on the other hand results form 
our and similar studies may further guide regulatory measures to improve drug safety. 
 
Our study is also subject to limitations. First, given the size of the dataset, it was not feasible to 
evaluate all 8’840 identified distinct interactions in detail, or to even manually search for 
interactions beyond those identified by MediQ. However, we are about to conduct additional 
studies that compare mass analyses by several different CDSS. Our study was also not designed 
to capture ADE associated with drug interactions, and this outcome will therefore have to be 
addressed by studies that can validate ADE in original medical records. Another limitation 
related to MediQ’s structure is that interactions between more than two concomitant substances 
at a time are not identified as such and the resulting risks may therefore be underestimated. 
However, ZHIAS was designed with that issue in mind, because the extended information on 
specific ADE can readily identify and display the additive risk of two interactions that may cause 
the same ADE, e.g. serotonin syndrome. Furthermore, also genetic and environmental factors 
such as smoking could influence the relevance of some interactions. MediQ is able to consider 
genetic factors, but our data did not contain such information, and genetic testing is rarely 
performed in psychiatric patients anyway because the few established indications do not include 
psychiatric drugs (23). However, it is possible that for example the risk of an ADE related to an 
interaction via CYP2D6 inhibition is modified by polymorphisms associated with CYP2D6 poor 
metabolizer status, and CDSS should also consider such information. Finally, the absence of a 
gold standard is a challenge for all attempts to classify drug interactions. Poor accordance 
between different systems has been demonstrated (24-26), and even within the same system 
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interrater variability must be expected (19, 27). This also applies to ORCA, where our personal 
assessment as part of ZHIAS sometimes deviated from Hansten & Horn’s ORCA class. 
However, we minimized the subjective component by an expert panel using comprehensive 
current references. In that context we also point out that in some cases our assignments to ORCA 
classes 1 or 2 were primarily driven by limited evidence on a drug’s benefit, or by a lack of 
efficacy, for example when oral midazolam is combined with carbamazepine (28). Similarly, a 
combination of two benzodiazepines may not imply a high risk of an ADE, but the classification 
as „provisionally contraindicated“ emphasizes that the extra risk is usually unnecessary unless 
one consciously combines different benzodiazepines based on the differences in their 
pharmacokinetics and therefore indications, e.g. long-acting for anxiolysis during the day and 
short-acting for sleep induction. 
 
In conclusion, our study quantified drug interactions in a large population with a new and highly 
efficient solution for automated mass analysis based on the CDSS MediQ. On the one hand this 
approach opens new opportunities for population-based prevalence estimations of critical drug 
combinations. On the other hand results of such retrospective analyses combined with new 
interaction classifications such as ZHIAS may support the development of customized CDSS 
that reduce over-alerting, focus on clinically relevant management recommendations for 
interacting combinations, and therefore improve the efficacy of CDSS to reduce ADE and costs 
caused by interactions. 
 
 
 
METHODS 
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Study design 
We conducted a retrospective analysis of drug interactions in a large cross-sectional prescription 
dataset from psychiatric inpatients that had been collected through the international AMSP 
(Arzneimittelsicherheit in der Psychiatrie, “Drug Safety in Psychiatry”) network. The ethics 
committee had approved the study with a waiver of authorization. 
An overview of the study procedures and global results is presented in Figure 1. After extensive 
formatting of the raw dataset, we performed an automated mass analysis for interactions. For that 
purpose we had developed a customized data interface for use with the CDSS MediQ (29). 
Subsequently we were able to describe all interactions that MediQ had identified along with their 
severity grading. Thereafter, all interactions classified by MediQ as “high danger” and the 20 
most frequent interactions classified as “average danger” were reclassified and evaluated by an 
expert group using the Zurich Interaction System (ZHIAS), a new extended multidimensional 
drug interaction classification. ZHIAS also incorporates the well-established Operational 
Classification of Drug Interactions (ORCA) (18). 
 
Data Source 
AMSP is an ongoing international multicenter drug safety program that has been collecting data 
on pharmacotherapy and ADE from psychiatric hospitals in a naturalistic setting since 1993. Its 
methods have been described in detail elsewhere (30, 31). Briefly, AMSP consists of two 
principle data collections from more than 80 hospitals in Germany, Switzerland and Austria, and 
more recently also from one hospital each in Belgium and Hungary. First, in a cross-sectional 
approach all participating hospitals survey psychiatric inpatients on two reference days per year. 
All drugs administered on these days are recorded along with the patients’ age, gender and 
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leading psychiatric diagnoses. Second, severe ADE occurring at these hospitals during 
psychopharmacological drug treatment are continuously reported and collected. For the current 
study we used only the cross-sectional prescription data with information from 88’029 patients 
surveyed between 1994 and 2008. 
 
Data management 
We received the original AMSP raw dataset as a tabulated list comprising 334'056 rows, where 
each row represented a prescription for a single commercial drug product, provided as its 
uniquely identifying trade name. Further columns provided an anonymous case identifier and 
additional information including age, gender and ICD-10 encoded psychiatric diagnoses. We 
assigned International Nonproprietary Names (INN) of active pharmaceutical ingredients to each 
prescription by consulting original national drug compendia and lists of commercial drug 
products with their corresponding active ingredients. For combination products that contain more 
than one active ingredient we programmed an algorithm that split those combination drugs, 
generating a new set of cases where each row represents the prescription of a single active 
ingredient. In order to transform the prescription data to a format that was compatible with the 
MediQ data interface for mass analysis, we assigned each substance its corresponding 
Anatomical Therapeutic Chemical (ATC) Classification code. Even though ATC codes can be 
redundant for single substances because they may consider additional information such as route 
of administration or indication, MediQ’s interaction algorithms are primarily based on substance 
information, whereas the role of dose, indication and route of administration relevant to its 
interactions may be discussed in the free text comments. 
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MediQ and development of a data interface for mass analysis of drug interactions 
MediQ is a commercial CDSS, designed for use via the Internet but without integrated 
computerized prescription order entry (CPOE). Its database contains about 2,000 specific 
substances and about 20,000 detailed comments on related interactions, including interactions 
with about 50 genetic polymorphisms. While being formally independent of the AMSP program, 
MediQ has been developed in the environment of a psychiatric hospital that is part of the AMSP 
network. Its content therefore has a particular focus on drugs that are commonly used in 
psychiatric patients, which made it particularly suitable for the current study. After manually 
entry of concomitantly prescribed drugs MediQ identifies interactions and provides the following 
output. First, a four-level categorical severity grading that MediQ describes as: 3 = ”high danger” 
or “strong interaction”; 2 = ”average danger” or “clinically relevant interaction”; 1 = “low 
danger” or an interaction that is “relevant in exceptional cases”; 0 = “no interaction” (well 
documented) or comments regarding a possible but poorly documented interaction of 
questionable clinical relevance. This information is also presented in a matrix overview. Second, 
detailed free text information for each interaction. Third, additional tables present 
pharmacokinetic effects on metabolizing enzymes and drug transporters as well as 
pharmacodynamic effects on the central nervous system for individual substances.  
Because the manual entry of prescriptions for each patient would not be feasible for the large 
number of patients analyzed in this study, we conjointly developed a customized interface for 
mass analysis. This allowed us to upload structured text files over the Internet that contained a 
unique anonymous case identifier and the ATC codes of concomitantly prescribed drugs for 
several thousand patients at a time. Exactly the same analyses as for the usual Internet 
application were then executed on the MediQ server. The results could be downloaded over the 
Internet and subsequently imported into statistical software for further analyses. Because 
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MediQ’s knowledge database is continuously updated it is of note that the analyses presented in 
this study were all executed during October and November 2010. 
 
 
ZHIAS classification 
ZHIAS is an extended drug interaction classification system that was developed at our 
department during the conduct of this and other related studies. It features four major dimensions 
plus free text fields. The first dimension uses the well-established five-level grading according to 
the Operational Classification of Drug Interactions (ORCA) criteria (18). Briefly, ORCA’s five 
operational levels are defined as follows: Grade 1 = “contraindicated combination”. The risk 
associated with the drug interaction always outweighs the benefit. Grade 2 = “provisionally 
contraindicated”. The combination should be avoided unless the interaction is desired or no 
alternative is available, monitoring may be necessary. Grade 3 = “conditional risk”, depending 
on individual patient factors. Monitoring or alternatives should be considered. Grade 4 = 
“minimal risk”. No special action is needed. Grade 5 = “no interaction”. ZHIAS’ other three 
major dimensions use dichotomous variables that relate to patient management, interaction 
mechanisms and expected ADE.  For the current study an expert panel consisting of a pharmacist 
(PH), a psychiatrist (WG), and a clinical pharmacologist (SR) discussed the ZHIAS 
classifications of identified interactions until mutual agreement was achieved. For our 
assessments we referred to original and secondary literature, including but not limited to Hansten 
and Horn’s Drug Interactions: analysis and management (21) and Stockley’s Drug Interactions 
(32). 
 
Data analysis 
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Descriptive statistics were used to summarize the results from the MediQ interaction analysis 
and the ZHIAS reclassification. In order to describe a drug’s intrinsic association with the 
generation of interaction alerts we calculated a drug interaction index (number of MediQ “high 
danger” warnings caused by a given drug divided by the total number of prescriptions for this 
drug in the study population) and the proportion of patients exposed to a given drug with at least 
one “high danger” interaction alert caused by that drug. Additional analyses with stratifications 
over calendar years addressed trends over time. The chi-square test was used to compare 
dichotomous variables between two strata. Data management, analyses, tables and graphs were 
done using SPSS 18 for MacOS X (IBM Corporation, Somers, NY, USA) and STATA 11.1 for 
MacOS X (STATA Corporation, College Station, TX, USA). 
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SUPPLEMENTARY MATERIAL 
Tables E1 to E4 and Figures E1 and E2 are foreseen as supplementary data for online 
publication. 
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AG, Lundbeck (Suisse) AG, Mepha Pharma AG, Organon AG, Pfizer AG, Pharmacia, Sanofi-
Aventis (Suisse) S.A., Sanofi-Synthélabo SA, Servier SA, SmithKlineBeecham AG, Solvay 
Pharma AG, Wyeth AHP (Suisse) AG, Wyeth Pharmaceuticals AG. 
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FIGURE LEGENDS 
 
Figure 1  Overall study design, procedures and global results. 
 
 
Figure 2  Pie charts showing the assignment to ORCA classes according to ZHIAS for all 
distinct interactions identified and classified by MediQ as “high danger” (n = 201) (a), and of 
the 20 most frequent interactions classified as “average danger” (b). 
 
 
Figure 3  Time trends for polypharmacy and high danger interaction alerts according to MediQ. 
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TABLES 
 
Table 1  The top 20 drugs most frequently associated with high danger interaction alerts 
in the study population according to MediQ. 
 
Rank Drug  total n 
prescriptions  
in the study 
population 
n prescriptions 
involved in 
MediQ high danger 
interaction alerts 
Proportion of all 
2,308 high danger 
interactions where 
drug is involved (%) 
     
1 Clozapine 7,453 648 28.1 
2 Fluvoxamine 881 430 18.6 
3 Lithium 5,725 316 13.7 
4 Paroxetine 2,590 191 8.3 
5 Hydrochlorothiazide 3,571 190 8.2 
6 Olanzapine 10,604 180 7.8 
7 Metoprolol 3,887 174 7.5 
8 Pimozid 273 146 6.3 
9 Thioridazine 471 131 5.7 
10 Amitriptylin 2,869 126 5.5 
11 Spironolactone 309 119 5.2 
12 Doxepin 2,842 113 4.9 
13 Moclobemide 484 105 4.5 
14 Trimipramin 3,193 103 4.5 
15 Tranylcypromine 328 102 4.4 
16 Carbamazepine 5,994 87 3.8 
17 Fluoxetine 1,350 78 3.4 
18 Amiodarone 109 77 3.3 
19 Sotalol 256 75 3.2 
20 Clomipramin 1,303 74 3.2 
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Table 2  The top 20 drugs bearing the greatest intrinsic risk for high danger interactions 
after adjustment for total number of prescriptions based on MediQ alerts	  	  
Rank Drug n prescriptions n high 
danger 
alerts 
Drug 
interaction 
index1 
Proportion of 
patients with high 
danger alert2 (%) 
      
1 Amiodarone 109 77 0.71 49.5 
2 Pimozide 273 146 0.53 47.6 
3 Fluvoxamine 881 430 0.49 48.8 
4 Mycophenolic acid 21 9 0.43 42.9 
5 Spironolactone 309 119 0.39 36.5 
6 Didanosine 36 12 0.33 33.3 
7 Saquinavir 6 2 0.33 33.3 
8 Erythromycin 37 12 0.32 27.8 
9 Tranylcypromine 328 102 0.31 29.7 
10 Ritonavir 64 20 0.31 29.7 
11 Meprobamat 35 11 0.31 31.4 
12 Sotalol 256 75 0.29 26.5 
13 Sibutramine 7 2 0.29 28.6 
14 Terfenadine 7 2 0.29 28.6 
15 Thioridazine 471 131 0.28 27.1 
16 Moxifloxacin 22 6 0.27 27.3 
17 Miconazol 4 1 0.25 25.0 
18 Nelfinavir 13 3 0.23 23.1 
19 Tenofovir 55 12 0.22 21.8 
20 Itraconazol 9 2 0.22 22.2 
 
 
1 Number of MediQ high danger warnings triggered by that drug divided by total number of its 
prescriptions in the study population. 
 
2 Proportion of patients exposed to the drug with at least one high danger interaction alert triggered by 
that drug. In addition to the Drug Interaction Index, this measure may be particularly useful from a clinical 
point of view when confronted with a patient exposed to that drug. 
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Table 3  The top 20 drug combinations most frequently associated with high danger 
interaction alerts in the study population according to MediQ. 
  Frequency of interactions  
Rank Drug combinations with high 
danger interaction according  
to MediQ 
n (%) Cum. % 
Adverse event with increased 
risk 
      
 TOTAL 2,308 (100)   
      
1 Clozapine – Fluvoxamine 402 (17.4) 17.4 Seizures and other CNS effects, 
QTc/TdP and arrhythmias, bone 
marrow toxicity 
2 Lithium – Hydrochlorothiazide 190 (8.2) 25.6 Seizures and other CNS effects, 
QTc/TdP and arrhythmias, (lithium 
intoxication) 
3 Olanzapine – Clozapine 177 (7.7) 33.3 QTc/TdP and arrhytnmias, 
hypotension, metabolic and 
endocrine disorders incl. blood 
glucose 
4 Metoprolol – Paroxetine 114 (4.9) 38.3 Hypotension 
5 Clozapine – Pimozide 68 (2.9) 41.2 EPS and other CNS effects, 
QTc/TdP and arrhythmias 
6 Torasemide – Lithium 60 (2.6) 43.8 Seizures and other CNS effects, 
QTc/TdP and Arrhythmias, (lithium 
intoxication) 
7 Levomepromazin – Doxepin 58 (2.5) 46.3 Sedation, hypotension 
8 Metoprolol – Fluoxetine 48 (2.1) 48.4 Hypotension 
9 Ramipril – Spironolactone 42 (1.8) 50.2 Hypotension, hyperkalemia 
10 Phenytoine – Valproate 40 (1.7) 51.9 Hepatotoxicity 
11 Amitriptyline – Tranylcypromine 39 (1.7) 53.6 Serotonine syndrome 
12 Amitriptyline – Moclobemid 38 (1.6) 55.3 Serotonine syndrome 
13 Moclobemid – Trimipramine 38 (1.6) 56.9 Serotonine syndrome 
14 Duloxetine – Tramadol 35 (1.5) 58.4 Serotonine syndrome 
15 Tranylcypromine – Carbamazepine 31 (1.3) 59.8 Seizures and other CNS effects 
16 Spironolacton – Potassium 30 (1.3) 61.1 Hyperkalemia 
17 Trimipramine – Thioridazine 28 (1.2) 62.3 QTc/TdP and arrhythmias 
18 Amitriptyline – Thioridazine 22 (1.0) 63.3 QTc/TdP and arrhythmias 
19 Doxepin – Thioridazine 21 (0.9) 64.2 QTc/TdP and arrhythmias 
20 Nefazodone – Carbamazepine 21 (0.9) 65.1 Loss of nefazodone efficacy 
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Table 4  ZHIAS reclassification by ORCA categories of all 2,3081 interactions classified by 
MediQ as high danger and their corresponding frequencies in the study population. 	  
ZHIAS classification Stratification over ORCA class 
    
 ORCA 1 ORCA 2 ORCA 3 
 n (%) n (%) n (%) 
TOTAL combinations 151 (100) 1,453 (100) 691 (100) 
    
Management    
Desired 0 (0) 335 (32.8) 97 (14.0) 
Consider alternative 151 (100) 1,130 (68.0) 605 (87.6) 
Monitoring 0 (0) 1,405 (96.8) 686 (99.3) 
    
Mechanism2    
Pharmacokinetic 69 (54.3) 1,172 (80.7) 346 (50.1) 
Pharnacodynamic 104 (68.9) 1,037 (71.4) 472 (68.3) 
    
Adverse events with increased risk associated with interactions3 
Increased drug effect 31 (36.0) 1,180 (77.7) 320 (46.3) 
Decreased drug effect 18 (20.9) 12 (0.8) 88 (12.7) 
Sedation, respiratory depression 1 (1.2) 95 (6.3) 65 (9.4) 
Serotonin syndrome 3 (3.5) 235 (15.5) 74 (10.7) 
Extrapyramidal symptoms 1 (1.2) 104 (6.9) 0 (0) 
Seizures 8 (9.3) 630 (41.5) 92 (13.3) 
CNS effects other 16 (18.6) 742 (48.9) 169 (24.5) 
Nephrotoxicity 0 (0) 0 (0) 3 (0.4) 
Hepatotoxicity 0 (0) 0 (0) 40 (5.8) 
QTc prolongation 41 (47.7) 1,110 (73.1) 288 (41.7) 
Cardiac arrhythmias 41 (47.7) 1,117 (73.6) 292 (42.3) 
Thrombosis 0 (0) 0 (0) 5 (0) 
Blood pressure up 3 (3.5) 29 (1.9) 0 (0) 
Blood pressure down 0 (0) 359 (23.6) 165 (23.9) 
Cardiovascular effects other 1 (1.2) 0 (0) 0 (0) 
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Hyperkalemia 0 (0) 0 (0) 129 (18.7) 
Hypokalemia  0 (0) 15 (1.0) 3 (0.4) 
Hyponatremia 0 (0) 1 (0.1) 24 (3.5) 
Gastrointestinal toxicity 0 (0) 5 (0.3) 0 (0) 
Blood glucose up 0 (0) 178 (11.7) 0 (0) 
Blood glucose down 0 (0) 177 (11.7) 0 (0) 
Muscular toxicity 0 (0) 2 (0.1) 7 (1.0 
Hematotoxicity 0 (0) 7 (0.5) 12 (1.7) 
Loss of therapeutic efficacy 37 (43) 17 (1.1) 48 (6.9) 
Other 1 (1.2) 38 (2.5) 14 (2.0) 
 
1 Another 13 interactions classified by MediQ as “high danger” were reclassified into ORCA 4 and not 
shown in detail in this table 
2 PK and PD mechanisms can be involved concomitantly and combined total may therefore exceed 100% 
3 Categories are not mutually exclusive and can in part overlap, e.g. for QTc prolongation and arrhythmia 
 
